Last reviewed · How we verify
C. albicans
At a glance
| Generic name | C. albicans |
|---|---|
| Sponsor | Genentech, Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Effect of Printing Layer Thickness on Growth of Candida Albicans in Completely Edentulous Patients Rehabilitated With 3D-Printed Maxillary Complete Denture Bases. (NA)
- Candin for the Treatment of Common Warts (PHASE3)
- Immunotherapy in Eyelid Viral Papilloma (PHASE2)
- Effect of Crown Material on Gingival Microbial Colonization (NA)
- Cleanser for Acute Wounds (NA)
- First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults (PHASE1)
- A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System® (PHASE2)
- Evaluation of the Effect of Labio-Lingual Spring Hawley and Clear Aligners on Periodontal Health and Salivary Parameters (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- C. albicans CI brief — competitive landscape report
- C. albicans updates RSS · CI watch RSS
- Genentech, Inc. portfolio CI